Use of Diuretics and the Risk of Gouty Arthritis: A Systematic Review

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 6, 2012, Pages 879-889

  Hueskes, Berdine A A ^a,b   Roovers, Elisabeth A ^b   Mantel Teeuwisse, Aukje K ^a   Janssens, Hein J E M ^c,d   van de Lisdonk, Eloy H ^c   Janssen, Matthijs ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Department of Rheumatology ^*  (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Primary Care Health Centre Lobede   (Netherlands)

Author keywords

Diuretics; Gouty arthritis; Hyperuricemia; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; BENDROFLUMETHIAZIDE; CYCLOSPORIN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LOOP DIURETIC AGENT; PLACEBO; PREDNISONE; THIAZIDE DIURETIC AGENT; URATE; URIC ACID;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; GENDER; GOUT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SAMPLE SIZE; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL;

ARTHRITIS, GOUTY; COHORT STUDIES; DIURETICS; HUMANS; RISK;

EID: 84861225023     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.11.008     Document Type: Article

References (48)

1. Gaffo A.L., Saag K.G. Management of hyperuricemia and gout in CKD. Am J Kidney Dis 2008, 52:994-1009.
2. Janssens H.J.E.M., Janssen M., van de Lisdonk E.H., van Riel P.L.C.M., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008, 371:1854-1860.
3. Luk A.J., Simkin P.A. Epidemiology of hyperuricemia and gout. Am J Manag Care 2005, 11:S435-S442. quiz S465-8.
4. Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
5. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35. National arthritis data workgroup.
6. Terkeltaub R.A. Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.
7. Schumacher H.R. Crystal-induced arthritis: an overview. Am J Med 1996, 100:46S-52S.
8. Teng G.G., Nair R., Saag K.G. Pathophysiology, clinical presentation and treatment of gout. Drugs 2006, 66:1547-1563.
9. Jansen Dirken-Heukensfeldt K.J.M., Teunissen T.A.M., Van de Lisdonk E.H., Lagro-Janssen A.L.M. Clinical features of women with gout arthritis. A systematic review. Clin Rheumatol 2010, 29:575-582.
10. Choi H.K., Mount D.B., Reginato A.M. Pathogenesis of gout. Ann Intern Med 2005, 143:499-516. American College of Physicians, American Physiological Society.
11. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009, 48(Suppl 2):ii2-ii8.
12. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003, 17:397-414.
13. El-Sheikh A.A.K., Van den Heuvel J.J.M.W., Koenderink J.B., Russel F.G.M. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008, 155:1066-1075.
14. Steele T.H., Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med 1969, 47:564-574.
15. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190.
16. Ichida K. What lies behind serum urate concentration?. Insights from genetic and genomic studies. Genome Med 2009, 1:118.
17. Hagos Y., Stein D., Ugele B., Burckhardt G., Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007, 18:430-439.
18. Whitworth J.A. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992. World Health Organization, International Society of Hypertension Writing Group.
19. Langford H.G., Blaufox M.D., Borhani N.O., Curb J.D., Molteni A., Schneider K.A., et al. Is thiazide-produced uric acid elevation harmful?. Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987, 147:645-649.
20. Campion E.W., Glynn R.J., DeLabry L.O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987, 82:421-426.
21. Roubenoff R., Klag M.J., Mead L.A., Liang K.Y., Seidler A.J., Hochberg M.C. Incidence and risk factors for gout in white men. JAMA 1991, 266:3004-3007.
22. Pascual E., Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006, 65:981-982.
23. Roddy E., Zhang W., Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007, 3:443-449.
24. Rott K.T., Agudelo C.A. Gout. JAMA 2003, 289:2857-2860.
25. Choi H.K., Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008, 336:309-312.
26. Genees-en hulpmiddelen Informatie Project (GIP) College van Zorgverzekeringen, (accessed 10 September 2009). http://www.gipdatabank.nl/.
27. Van de Lisdonk E.H., van den Bosch W.J.H.M., Lagro-Janssen A.L.M., Schers H.J. Ziekten in de huisartspraktijk. 5e druk 2008, Elsevier gezondheidszorg, Maarssen.
28. Slavin R.E. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 1995, 48:9-18.
29. Checklists The Dutch Cochrane Centre, (accessed 7 September 2009). http://www.cochrane.nl/nl/index.html.
30. Gurwitz J.H., Kalish S.C., Bohn R.L., Glynn R.J., Monane M., Mogun H., et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997, 50:953-959.
31. Zhang W., Doherty M., Pascual E., Bardin T., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part I: Diagnosis Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311.
32. Janssens H.J.E.M., Janssen M., van de Lisdonk E.H., Fransen J., van Riel P.L.C.M., van Weel C. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2010.
33. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yü T. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
34. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981, 2:539-543. Medical Research Council Working Party on Mild to Moderate Hypertension.
35. Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991, 90:50S-54S.
36. Fletcher A., Amery A., Birkenhager W., Bulpitt C., Clement D., de Leeuw D., et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991, 9:225-230.
37. Serum uric acid: its association with other risk factors and with mortality in coronary heart disease. J Chronic Dis 1976, 29:557-569. The Coronary Drug Project Research Group.
38. Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005, 165:742-748.
39. Gores P.F., Fryd D.S., Sutherland D.E., Najarian J.S., Simmons R.L. Hyperuricemia after renal transplantation. Am J Surg 1988, 156:397-400.
40. Grodzicki T., Palmer A., Bulpitt C.J. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group. J Hum Hypertens 1997, 11:583-585.
41. Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000, 27:1501-1505.
42. Hanly J.G., Skedgel C., Sketris I., Cooke C., Linehan T., Thompson K., et al. Gout in the elderly-a population health study. J Rheumatol 2009, 36:822-830.
43. Hunter D.J., York M., Chaisson C.E., Woods R., Niu J., Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006, 33:1341-1345.
44. Janssens H.J., van de Lisdonk E.H., Janssen M., van den Hoogen H.J., Verbeek A.L. Gout, not induced by diuretics?. A case-control study from primary care. Ann Rheum Dis 2006, 65:1080-1083.
45. Stamp L., Ha L., Searle M., O'Donnell J., Frampton C., Chapman P. Gout in renal transplant recipients. Nephrology (Carlton) 2006, 11:367-371.
46. Suppiah R., Dissanayake A., Dalbeth N. High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J 2008, 121:43-50.
47. Scott J.T., Higgens C.S. Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 1992, 51:259-261.
48. Waller P.C., Ramsay L.E. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989, 3:457-461.